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ABSTRACT 
Glutamine, the most abundant amino acid in mammals, is critical for cell and organ 
functions. Its metabolism depends on the ability of cells to take up or release 
glutamine by transporters located in the plasma membrane. Several solute carrier 
(SLC) families transport glutamine, but the SLC38 family has been thought to be 
mostly responsible for glutamine transport. We demonstrate that despite the large 
number of glutamine transporters, loss of the Snat3/Slc38a3 glutamine transporter 
has a major impact on the function of organs expressing it. Snat3 mutant mice were 
generated by N-ethyl-N-nitrosurea (ENU) mutagenesis and showed stunted growth, 
altered amino acid levels, hypoglycemia, and died around 20 days after birth. Hepatic 
concentrations of glutamine, glutamate, leucine, phenylalanine, and tryptophan were 
highly reduced paralleled by downregulation of the mTOR pathway possibly linking 
reduced amino acid availability to impaired growth and glucose homeostasis. Snat3 
deficient mice had altered urea levels paralleled by dysregulation of the urea cycle, 
gluconeogenesis, and glutamine synthesis. Mice were ataxic with higher glutamine 
but reduced glutamate and GABA levels in brain consistent with a major role of Snat3 
in the glutamine-glutamate cycle. Renal ammonium excretion was lower and 
expression of enzymes and amino acid transporters involved in ammoniagenesis 
were altered. Thus, SNAT3 is a glutamine transporter required for amino acid 
homeostasis and determines critical functions in various organs. Despite the large 
number of glutamine transporters, loss of Snat3 cannot be compensated suggesting 
that this transporter is a major route of glutamine transport in liver, brain, and kidney.  
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INTRODUCTION 
Glutamine is the most abundant amino acid in the human body and is involved 
in more physiological processes than any other amino acid [1-3]. Glutamine serves 
as a precursor of purines, pyrimidines, glycogen, glucose, and in protein synthesis [4] 
and is involved in a myriad of other metabolic processes. It is also a major regulator 
of key physiologic processes such as hepatic and renal gluconeogenesis, the 
glutamate/GABA-glutamine cycle in the central nervous system (CNS) [5], hepatic 
ammonia detoxification [6], and in renal response to acidosis [7]. Furthermore, 
glutamine is the major oxidative fuel for rapidly replicating cells such as enterocytes 
and cells of the immune system, providing ATP for intracellular protein turnover, 
nutrient transport through the plasma membrane, cell growth and migration as well as 
the maintenance of cell integrity [1, 8]. Finally, glutamine is also a key intermediate in 
interorgan nitrogen and carbon transport [9-10]. The transport of glutamine across 
cell membranes is mediated by several amino acid carriers with different specificity 
for glutamine and other neutral amino acids. To date, at least 4 distinct SLC 
transporter families have been implicated in glutamine transport, the SLC1 family of 
glutamate and glutamine transporters, the SLC3-SLC7 heterodimeric family, the 
SLC6 family of neurotransmitter and neutral amino acid transporters, and the SLC38 
family of glutamine transporters [11-12]. The SLC38 family has at least two major 
subgroups, the system A transporter of Na+-coupled transporters including SNAT1 
(SLC38A1), SNAT2 (SLC38A2), and SNAT4 (SLC38A4) and the system N 
transporter family of Na+- and H+-coupled transporters SNAT3 (SLC38A3), SNAT5 
(SLC38A5), and SNAT7 (SLC38A7) [13]. Whereas system A transporters have a 
wider substrate spectrum including glutamine, alanine, asparagine, cysteine, serine, 
methionine, proline, glycine, and histidine, the specificity of system N transporters is 
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narrow transporting only glutamine, histidine, asparagine, and serine [12]. These 
system N amino acid transporters mediate the uptake of 1 glutamine molecule with 
the net uptake of 1 Na+ in exchange of a proton. The other members of the SLC38 
family, the system A transporters (SNAT1, SNAT2, SNAT4) are not able for counter-
transport of protons [13-16]. SNAT3 is highly abundant in liver, kidney, and brain, and 
expression has also been reported for adipose tissue, pancreas, skeletal muscle, and 
eye. In kidney, SNAT3 is mainly localized to the proximal tubule, in liver to both 
perivenous and periportal hepatocytes, and in brain mostly in astrocytes and 
endothelial cells of the blood-brain-barrier [17-21]. In the brain, SNAT3 and SNAT5 
have been hypothesized to be responsible for the efflux of glutamine from astrocytes 
which is a crucial step in the recycling of glutamate and GABA neurotransmitters 
between astrocytes and neurons [5, 22]. In the liver, SNAT3 is likely to be a 
candidate for both periportal uptake and perivenous efflux of glutamine, which is 
essential for the detoxification of ammonia delivered via the portal blood and 
excreted as urea [6, 21]. Furthermore, SNAT3 mRNA and protein expression in the 
kidney is increased in response to metabolic acidosis possibly providing glutamine for 
ammoniagenesis in the proximal tubule cell [18, 20, 23-24]. Plasma glutamine levels 
decrease substantially during metabolic acidosis [25] and glutamine flow is redirected 
from the splanchnic bed to the kidney with SNAT3 proposed to deliver glutamine for 
renal ammoniagenesis. 
To date, all studies addressing the function and regulation of SLC38 amino 
acid transporters have used either heterologous expression systems or cell culture 
models. The biological relevance of these transporters, however, has not been 
examined in any in-vivo model to the best of our knowledge. Here we demonstrate 
Central role of Snat3 in glutamine homeostasis 
 
5 
 
that SNAT3 plays a critical role in glutamine transport and metabolism by 
characterizing a mouse model deficient of Slc38a3.  
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MATERIALS AND METHODS 
 
Animals. Snat3 mutant mice (Q263X, Hybrid C3H-C57BL/6J) were generated by 
Ingenium Pharmaceuticals AG (Martinsried, Germany) using ENU-mutagenesis. The 
mutation causes a premature stop codon at amino acid position 263 deleting the 
second half of the protein (Fig. 1B).  Animals were maintained at 22 ± 2°C and a 
12:12 h light/dark cycle with access to tap water and standard rodent diet ad libitum 
(Provimi KLIBA, Kaiseragust, Switzerland). Mice were continuously backcrossed to 
C57BL6/J and animals from the 6 to 10th generation were used for this study. For all 
experiments littermates were used from heterozygous breeding. Analysis of the 
offspring from heterozygous mating suggested that the ratio of genotypes obtained 
followed almost a Mendelian inheritance (wildtype (WT) 15%, Snat3+/- 56%, Snat3-/- 
29%; n = 52 pups analyzed). All animal procedures were carried out according to the 
Swiss Animal Welfare laws and approved by the local veterinary authority 
(Kantonales Veterinäramt Zurich). 
 
mRNA analysis by semi-quantitative real time PCR. Snap-frozen tissue was 
homogenized in 1 ml RLT-buffer (Qiagen, Netherland) supplemented with 2- using 
RNeasy Mini Kit (Qiagen, Netherland) following the manufacturer’s instructions. 
Quality, purity and concentration of the isolated RNA were assessed susing the ND-
1000 spectrophotometer (NanoDrop technologies, USA).  
 
Each RNA sample was diluted to 100 ng/µl and 3 µl was used as a template for 
reverse transcription using the TaqMan Reverse Transcription Kit (Applied 
Biosystems, USA). Reverse transcription was performed  with the Biometra 
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TGradient thermocycler with termocycling conditions set at 25°C for 10 min, 48°C for 
30 min, and 95°C for 5 min. Semi-quantitative real-time (RT-qPCR) was performed 
on the ABI PRISM 7700 Sequence Detection System (Applied Biosystem, USA). 
Thermocycling conditions were as follows: 50°C for 2 min, 95°C for 10 min, and 95°C 
for 15 s (40 cycles). Primers and probes for all genes were designed using Primer 3 
Software developed at Whitehead Institute and Howard Hughes Medical Institute and 
synthesized at Microsynth (Microsynth, Balgach,Switzerland). Probes were labeled 
with the reporter dye FAM at the 5’ end and the quencher dye TAMRA at the 3’ end 
(Microsynth, Balgach, Switzerland).  Reactions were run in triplicate, including a 
negative control (without Multiscribe reverse transcription enzyme). The gene 
expression was calculated in relation to hypoxanthine guanine phosphoribosyl 
transferase (HPRT). Relative expression were calculated as 2
[(Ct(HPRT)-Ct(test gene)]. 
Primers and probes are listed in Supplementary Table 1.  
 
Antibodies. The primary antibodies used were mouse monoclonal anti-ß-actin  (42 
kDa; Sigma-Aldrich, Saint-Louis, MO, USA; diluted 1:5000), mouse monoclonal anti-
tubuline antibody (50 kDa; Sigma-Aldrich, Saint-Louis, MO, USA; diluted 1:20000), 
rabbit polyclonal anti-PEPCK antibody (63 kDa; Cayman Chemicals, Ann Arbor, MI, 
USA; diluted 1:1000), rabbit polyclonal anti-PDG antibody (66 and 68 kDa; a kind gift 
from N. Curthoys, Colorado State University, Fort Collins, CO, USA [26]; diluted 
1:5000), rabbit polyclonal anti-GLS2 antibody (70 kDa; ProSci, Poway, CA, USA; 
diluted 1:2000), rabbit monoclonal anti-Glu1 (45 kDa; BD Transduction Laboratories, 
San Jose, CA, USA; diluted 1:5000), rabbit polyclonal anti EAAT2 antibody (53 kDa; 
Cell Signaling Technology, Boston, MA, USA; diluted 1:2000),  rabbit polyclonal anti-
EAAT3 antibody (Alpha Diagnostic International, San Antonio, TX, USA; diluted 
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1:2000),  polyclonal anti- total-S6K antibody (70 kDa, Cell Signaling Technology, 
Boston, MA, USA; diluted 1:5000), rabbit polyclonal anti-LAT1 (39 kDa; kind gift of N. 
Thompson, Brown University, Providence, RI, USA [27]; diluted 1:1000) and anti-
LAT2 (39 kDa; a kind gift from F. Verrey, Zurich University,, Switzerland, [28] ; diluted 
1:1000), rabbit polyclonal anti-phospho-p70 SK6 antibody (70 kDa, Cell Signaling 
Technology, Boston, MA, USA ; diluted 1:5000), rabbit polyclonal anti-total mTOR 
antibody (289 kDa; Cell Signaling Technology, Boston, MA, USA; diluted 1:5000) and 
rabbit polyclonal anti-phospho-mTOR antibody (289 kDa; Cell Signaling Technology, 
Boston, MA, USA; diluted 1:2000). Rabbit polyclonal anti-SNAT1 (55 kDa; kindly 
provided by F. Verrey, University of Zurich, Zurich, ZH, Switzerland [19]; diluted 
1:1000), rabbit polyclonal anti-SNAT3 (55 kDa; kindly provided by F. Verrey, 
University of Zurich, Zurich, ZH, Switzerland [20]; diluted 1:500). Secondary 
antibodies used were horseradish peroxidase-conjugated donkey anti rabbit or anti 
mouse (GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom; diluted 
1:10000) and goat alkaline phosphatase-conjugated anti-rabbit (Promega, Madison, 
WI, USA, diluted 1:5000), Alexa 593 anti-rabbit antibody (Invitrogen, Carlsbad, CA, 
USA); diluted 1:1000) and Alexa 488 donkey anti-goat antibody (Invitrogen Carlsbad, 
CA, USA; diluted 1:3000).  
 
Protein extraction and immunoblotting. Kidneys, liver and brain were removed from 
14 days old mice and rapidly frozen in liquid nitrogen. Total membrane and cytosolic 
proteins were prepared using a K-HEPES buffer  (200 mM mannitol, 80 mM K-
HEPES, 41 mM KOH, pH 7.5) containing  protease inhibitors (PMSF, K-EDTA, and 
leupeptin). The different organs were homogenized using a Rotor-stator 
homogenizer. Kidneys and liver homogenates were subsequently centrifuged for 20 
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min at 2,000 rpm at 4°C, whereas the brain was centrifuged for 30 min at 3,500 rpm 
at 4°C due to the high content of fat. The supernatant was ultra-centrifuged (Sorvall, 
Thermo Fisher Scientific,  Waltham, MA, USA) for 1h at 41,000 rpm at 4°C. The 
resulting supernatant containing the cytosolic proteins was removed and the pellet 
resuspended in K-HEPES buffer and sonicated briefly to homogenize the proteins 
solution. Total protein concentration was measured using the Bio-Rad DC protein 
assay (Bio-rad, Hercules, CA, USA). Fifty µg of crude membrane proteins were 
solubilized in 2X Laemmli sample buffer and SDS page was performed on either 6% 
or 10% polyacrylamide gels. Proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes (Immobilon-P, Milipore, Billerica, MA USA). After blocking with 
5% milk powder in Tris -buffered saline/01%  Tween-20 for 1h, blots were incubated 
with primary antibodies either at room temperature for 2h or overnight at 4°C. 
Membranes were then washed three times, blocked for 1h in 5% milk TBS tween, 
and incubated for 1h at room temperature with secondary antibodies. Membranes 
were treated with alkaline phosphatase or horseradish peroxidase-conjugated 
developing solution and exposed to the las4000 chemiluminescence detection 
system (Fujifilm, Tokyo, Japan). Specific bands on PVDF membranes were 
quantified using AIDA Image Analyser. Eventually membranes were stripped and 
reprobed with other antibodies. 
 
Immunochemistry. Anesthetized mice were perfused through the left cardiac ventricle 
with a phosphate-buffered saline (PBS, pH 7.4), followed by a 1 % 
paraformaldehyde/ 2.5 glutaraldehyde fixative solution. Kidneys, liver and brain were 
then harvested and left in the fixative solution overnight. Organs were embedded in 
O.C.T. Compound (Tissue-Tek, Sakura Finetek, Alphen aan den Rijn, Netherlands) 
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and store at -80C°. For staining, 3-µm-thick tissue sections were prepared using a 
vibrating microtome VT1000S (Leica, Aarau, AG, Switzerland) and mounted on 
polylysine-coated glass slides (Kindler, Freiburg, BW, Germany). Sections were 
treated in SDS for 5 min, blocked for 15 minutes with bovine serum albumin), and 
incubated with primary antibodies overnight at 4C°. Sections were washed three 
times with PBS/high salt (0.3 M NaCl) and once with PBS, then incubated with Alexa 
labeled secondary antibodies and 4',6-diamidino-2-phenylindole (DAPI, Invitrogen 
Carlsbad, CA, USA; diluted 1:1000) to mark cell nuclei. After washing sections twice 
with PBS/high salt and once with PBS, sections were mounted in an aqueous 
mounting medium (Glycergel, Dako, Glostrup, Denmark).  Sections were viewed on a 
Leica 5500B microscope (Leica, Aarau, AG, Switzerland) and pictures processed 
using Adobe photoshop. 
 
Amino acids measurements in plasma and organs. For quantification of amino acids 
a LC-MS/MS based method with aTRAQ® labeling (Reagent Kit, ABSciex, Foster 
City, USA) was employed [29]. For analysis of tissue amino acids (brain, liver, 
kidney) small pieces of tissues were homogenized in liquid nitrogen. 100 mg of 
homogenized tissue were dissolved in 150 µl MeOH/H2O (50/50, v/v), vortexed, and 
centrifuged. Sample preparation was done according to the manufacturer's 
instructions using 40 µl of the supernatant of the tissue homogenates or 40 µl 
plasma. Tissue amino acid concentrations were standardized with protein 
concentrations determined via Bradford assay (Bio-Rad Laboratories GmbH, 
Germany).   
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Plasma glucose, insulin and ammonium measurements. Blood glucose 
measurements were carried out using ACCU-CHEK Aviva Plus system (Roche, 
Basel, BS, Switzerland). Mice were anesthetized and one drop of blood from the tail 
vein was collected for glucose measurements. Plasma insulin measurements were 
performed using the ultra-sensitive mouse insulin ELISA kit according to the 
manufacturer's instructions (Crystal Chem, Downers Grove, IL, USA). Similarly, 
plasma ammonium measurements were performed using the Sigma ammonium 
assay kit according to the manufacturer’s instructions (Sigma-aldrich, Saint-Louis, 
MO, USA). 
 
Induction of metabolic acidosis. Wildtype and heterozygous Snat3 mutant mice were 
placed in metabolic cages for 4 days and urine collected under mineral oil on the last 
day for 24 hrs. One group of wildtype and mutant mice received only standard rodent 
chow and tap water ad libitum. A second group of mice received for the last two days 
0.28 M NH4Cl in drinking water to induce metabolic acidosis as described previously 
[30]. Animals were sacrificed and their kidneys harvested and immediately frozen. 
Urinary pH was measured using a pH microelectrode (691 pH-meters, Metronohm, 
Herisau, AR, Switzerland). Urinary creatinine was measured according to the Jaffe 
method [31]. Urinary ammonium was measured by the Berthelot method [32].   
 
Statistical analysis and graphs. Results are expressed as mean ± SEM. All data 
were tested for significance using the one-way ANOVA and Tukey post-test or 
unpaired student’s t-test where appropriate. Graps were generated using Prism 
GraphPad (La Jolla, CA, USA).  
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RESULTS 
 
Snat3 mutant mice die in the late weaning stage 
 Snat3 mRNA expression was first studied in wildtype mice. Real-time PCR 
confirmed a significant expression of Snat3 in brain, kidneys, eyes, skeletal muscles 
and the highest expression in liver (Fig. 1A). However, since 14 days old mice could 
not provide enough material for experiments on muscles and eyes, further studies 
were performed only on brain, kidneys, and liver. Mutant mice were obtained from 
screening a library of sperm generated using ENU mutagenesis [33]. Deletion of 
Snat3/Slc38a3 in mice was lethal; homozygous mutant mice (Snat3-/-) died between 
18 and 20 days after birth whereas no increased lethality was observed for 
heterozygous mice (Snat3+/-). Homozygous mutant mice were easily distinguishable 
by their small size (Fig. 1C), lower body weight at postnatal day 14 (WT: 8.1 ± 0.2 g; 
Snat3+/-: 8.2 ± 0.1g, and Snat3-/-: 5.1 ± 0.3 g; 7-33 animals/group, p < 0.001 for 
Snat3-/- vs.  WT or Snat3+/-) and a form of ataxia. In homozygous mutant mice, lower 
signals of Snat3 mRNA expression was detected by real-time PCR in the brain, liver 
and kidney (Fig. 1D-F). Western Blot analysis did not detect any Snat3 protein 
expression in tissue extracts of brain, liver and kidney from Snat3-/- mice, 
demonstrating that the mutation leads to the ablation of Snat3 expression (Fig. 1G-I). 
Interestingly, heterozygote mice (Snat3+/-) showed intermediate expression levels of 
Snat3 mRNA and protein. Furthermore, kidney sections from Snat3-/-  mice showed 
no staining for the transporter in the proximal tubule, hence confirming the deletion of 
the protein (Fig. 1J).  
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Snat3 deletion causes hypoglycemia and altered amino acids levels in mutant mice 
Because SNAT3 is an amino acid transporter, we expected that amino acid 
concentrations in the blood of mutant mice might be altered. Indeed, the plasma 
concentration of histidine (WT: 120.99 ± 12.09 vs. Snat3-/-: 469.36 ± 39.54 mmol/L), 
threonine (WT: 231.45 ± 26.81 vs. Snat3-/-: 293.92 ± 14.45 mmol/L), leucine (WT: 
133.36 ± 7.79 vs. Snat3-/-: 191.95 ± 26.84 mmol/L), cysteine (WT: 3.05 ± 0.04 vs. 
Snat3-/-: 3.31 ± 0.20 mmol/L), and carnosine (WT: 9.88 ± 0.78 vs. Snat3-/-: 20.50 ± 
3.03 mmol/L) was significantly higher in homozygous mutant mice whereas the 
concentration of tyrosine (WT: 150.32 ± 13.41 vs. Snat3-/-: 95.08 ± 9.47 mmol/L), 
alanine (WT: 778.82 ± 45.07 vs. Snat3-/-: 541.17 ± 26.83 mmol/L), and tryptophan 
(WT: 87.70 ± 4.43 vs. Snat3-/-: 67.30 ± 6.01 mmol/L) was significantly lower 
(Supplementary Table 2).  
 
 Next, we measured amino acid concentrations in liver to determine if changes 
in plasma amino acid concentrations would also correlate with changes in amino acid 
availability in this organ (Supplementary Table 3). Alanine (WT: 57.52 ± 9.72 vs. 
Snat3-/-: 28.99 ± 4.99 µmol.L-1/µg.µL-1), glutamine (WT: 84.02 ± 10.11 vs. Snat3-/-: 
36.73 ± 7.63 µmol.L-1/µg.µL-1), glutamate (WT: 67.40 ± 6.96 vs. Snat3-/-: 42.88 ± 
11.46 µmol.L-1/µg.µL-1), and asparagine (WT: 3.67 ± 0.32 vs. Snat3-/-: 1.82 ± 0.24 
µmol.L-1/µg.µL-1) were less abundant in the liver of Snat3-/-  mice. These amino acids 
are important substrates in gluconeogenesis and glycogen synthesis [4] and serve as 
inter-organ carriers of nitrogen and carbon [9]. As SNAT3 has been demonstrated to 
be regulated by insulin and serum starvation in hepatocytes [34], we analysed blood 
glucose and insulin levels in Snat3-/-, Snat3+/- , and wildtype mice. In comparison to 
their wildtype littermates, mutant mice showed a significant decrease of blood 
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glucose and insulin levels suggesting that SNAT3 is involved in glucose homeostasis 
(Fig.  3A and B). Therefore, we next examined the expression of enzymes involved in 
hepatic gluconeogenesis. Phosphoenol pyruvate carboxykinase (PEPCK) was up-
regulated significantly at both mRNA (Fig. 3C) and protein levels (Fig. 3F,G). In 
contrast, glutaminase 2 (GLS2) showed no changes at mRNA level (Fig. 3D) but the 
GLS2 protein was massively down-regulated in mutant mice (Fig. 3H,I). Surprisingly, 
glutamine synthetase 1 (GLU1) was strongly up-regulated at the mRNA level (Fig. 
3E) but down-regulated at the protein level (Fig. 3J,K).  
  
The mTOR pathway is reduced in Snat3 deficient mice.    
 Glutamine and other neutral amino acids are known to play a role in 
intracellular amino acid sensing. Since the mutant mice displayed altered plasma 
glucose and insulin levels and had reduced growth, we assumed that intracellular 
amino acid sensing via the mTOR pathway was affected [35-38]. Accordingly, 
leucine, phenylalanine, and tryptophane which can stimulate mTOR showed reduced 
levels in liver tissues of mutant mice (Fig. 4A-C). Additionally, the insulin-like growth 
factor 1 (IGF1) which is an activator of the mTOR pathway, was also down-regulated 
in Snat3-deficient mouse liver (Fig. 4D).  Moreover, total and the phosphorylated 
forms of mTOR were massively down-regulated in mutant mice compared to wildtype 
littermates (Fig. 4E-H). Whereas the non-phosphorylated form of the ribosomal 
protein S6 kinase (S6K) showed no difference between genotypes, the phosphor-
form of S6K was significantly less abundant in Snat3-deficient mice (Fig. 4I-L). The 
ratio of phospho-protein versus total protein was significantly lower in mutant mice for 
S6K whereas no difference was found for mTOR (Fig. 3M and N). This suggests that 
the decrease of phosphorylated mTOR parallels the decrease of total mTOR 
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expression whereas the decrease of phospho-S6K was due to a decrease in the 
phosphorylation state of this protein possibly because of a reduced mTOR activity. 
 
Mutant Snat3 mice show an altered hepatic urea cycle.  
 The liver is responsible for detoxification of ammonia by converting it into urea 
through the urea cycle [6]. Because SNAT3 is highly expressed in liver and is likely to 
be involved in the urea cycle, we examined the hepatic urea cycle in the mutant mice. 
Serum urea levels were substantially increased in mutant mice in comparison to 
littermates (Fig. 5A) but no difference was observed in plasma ammonium levels 
between genotypes (Fig. 5B). Hepatic carbamoyl phosphatesynthetase I (Cps1) and 
ornithine-transcarbamylase (Otc) mRNA expression showed no significant 
differences in mutant mice compared to wildtype animals, whereas argininosuccinate 
lyase (Asl), and arginase I (Arg1) levels were significantly increased in mutant mice 
(Fig 5C-F).  
 
The glutamate-glutamine cycle is defective in the brain of Snat3 deficient mice.   
 SNAT3 is highly expressed in brain astrocytes, and is believed to play a role in 
the glutamate-glutamine cycle involved in neurotransmission [5, 15, 22]. The lethargy 
and an altered, uncoordinated gait observed in mutant mice suggested impaired 
neurotransmission after Snat3 deletion in brain. We thus measured the 
concentrations of different amino acids and neurotransmitters involved in the 
glutamate-glutamine cycle (Supplementary Table 4). Glutamine abundance was 
higher whereas glutamate and gamma-aminobutyric acid (GABA) levels were lower 
in brains of mutant animals (Fig. 6A-C). We also assessed the expression of the 
glutamine and glutamate transporters implicated in the glutamate-glutamine cycle. 
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The system A transporters Snat1 and Snat2 showed no difference at mRNA levels in 
mutant mice when compared to wildtype and heterozygous littermates (Fig. 6D and 
E). Yet, Snat1 is expressed exclusively in neurons [16, 39-40] and was significantly 
up-regulated in the brain of mutant mice at the protein level (Fig. 6J and K). The 
system N transporter Snat5 was down-regulated at the mRNA level (Fig. 6F). No 
changes were observed at mRNA or protein levels in expression of any of the 
glutamate transporters Slc1a1 (Eaac1 or Eaat3) and Slc1a2 (Glt-1 or Eaat2) (Fig. 6G 
and H, L and M). The mRNA expression of glutamine synthetase (Glu1), which 
mediates the conversion of glutamate to glutamine in astrocytes, showed no 
difference between genotypes (Fig. 6I). Lastly, protein expression of the system L 
amino acid transporter 1 (LAT1) mediating the transport of neutral amino acids and 
expressed in brain vessels [41] and possibly also in neurons [42] was significantly 
increased in mutant mice when compared to wildtype (Fig. 6N and O).  
 
Impaired ammoniagenic pathway in kidney.   
  We next investigated the involvement of SNAT3 in ammoniagenesis in the 
kidney. Glutamine and glutamate were both less abundant in kidneys of Snat3-
deficient animals (Fig. 7A and B, Supplementary Table 5). Urine spot samples were 
collected as it was impossible to collect 24h urine samples from two-week old pups. 
Urinary NH4
+ and urea excretion was significantly reduced in homozygous Snat3 
mutant mice in comparison to wildtype and heterozygous littermates (Fig. 7C and D). 
The enzymes involved in ammoniagenesis: phosphate-dependent glutaminase (Pdg) 
showed elevated levels but no change in phosphoenolpyruvate carboxykinase 
(Pepck) in Snat3-/- mice (Fig. 7E,F). 
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The RhCG transporter is primarily expressed in the connecting tubule and the 
collecting duct, and plays an important role in apical NH4
+ extrusion into the final 
urine [43-44]. Mutant mice showed no changes in renal mRNA expression of Rhcg 
(Supplementary Fig. 1A). Snat2 and Snat5 are both highly expressed in the kidney 
and could potentially compensate for the loss of Snat3 function in mutant mice. 
However, no changes in mRNA expression were observed for Snat2 (Supplementary 
Fig. 1B). In contrast, Snat5 was significantly down-regulated in mutant mice 
compared to heterozygous and wildtype animals (Supplementary Fig. 1C). However, 
no specific antibodies were available to test protein abundance and renal localization. 
The system L Amino acid transporter 2 ( ), an antiporter for neutral amino acids 
expressed in the kidney [20] is likely involved in the efflux of glutamine from proximal 
tubular cells [28] and was found down-regulated at the protein level in mutant mice 
(Fig. 7G,H).  
 
Since homozygous mutant mice are not viable enough to perform acid-loading 
tests to stimulate ammoniagenesis and because heterozygous mutant mice showed 
reduced Snat3 protein expression, we tested if 12 week old heterozygous mice could 
adapt renal ammoniagenesis.  Wildtype and heterozygous mice were given NH4Cl for 
two days to induce a metabolic acid load. Both groups of mice consumed similar 
amounts of the NH4Cl drinking water and developed metabolic acidosis with similar 
falls in blood pH and blood bicarbonate (data not shown). Moreover, after 2 days of 
acid load, both wildtype and heterozygote mice showed a similar increase in total 
urinary NH4
+ excretion (Fig. 8A) and a decrease in urinary pH (Fig. 8B). However, 
renal Pdg and Pepck, but not Snat3, showed significantly higher mRNA levels in 
heterozygote mice after acid-loading compared to wildtype mice (Fig. 8C-E. This 
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suggests that a higher induction of these enzymes may be required to reach the 
same level of ammoniagenesis as in wildtype animals.  
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DISCUSSION 
 This is the first report on the deletion of a member of the SLC38 family of 
glutamine transporters in an animal. Several members of the SLC38 family have 
been studied extensively in heterologous and other in vitro systems [18, 20, 23, 34] 
but their function in vivo  is mainly unknown. Here we report a severe phenotype of 
mice lacking Snat3 due to an early stop codon introduced by random ENU-
mutagenesis. Mice deficient of Snat3 die early before weaning and display ataxia, 
multiple defects in amino acid homeostasis, glucose metabolism, glutamate-
glutamine cycle, and renal ammoniagenesis. Together, these impairments might 
explain the early death of mutant mice after 20 days of life. 
SNAT3 is an amino acid transporter with substrate specificity for glutamine, 
histidine, serine, and asparagine. Slc38a3 mutant mice had elevated plasma histidine 
levels whereas serine, glutamine, and asparagine levels remained unaltered.  These 
data indicate that the alterations in the plasma amino acid profile most likely reflect 
secondary changes in cellular metabolism. Glutamine levels in plasma may be 
unaltered because the pool of glutamine is large and because SNAT3 most likely 
serves as uptake transporter into renal proximal tubule cells and hepatocytes using 
glutamine as substrate for the urea cycle and gluconeogenesis (see below). In brain, 
SNAT3 serves the local recycling of glutamine and disruption of this function is not 
expected to alter systemic glutamine levels.     
 
 Snat3 deficient mice suffered from altered energy metabolism. Homozygous 
mutant mice were hypoglycemic and the decrease in plasma glucose may originate 
from a reduced hepatic capacity for gluconeogenesis. The low insulin levels 
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measured would be the appropriate compensation for this primary fall in glucose 
levels. The lack of Snat3 significantly lowered hepatic glutamine levels with glutamine 
as a main substrate for gluconeogenesis. The decrease in plasma and hepatic 
alanine content, the decrease in plasma insulin, the up-regulation of the 
gluconeogenic enzyme Pepck as well as the down-regulation of Gls2 observed in 
Snat3-deficient animals points to an increased use of alanine as a glucogenic amino 
acid due to reduced availability of glutamine. Hence, changes in alanine 
concentrations are most likely to be a secondary effect of  Snat3 deletion as alanine 
is not a substrate of SNAT3 [21, 45]. As the increased Snat5 expression observed 
disagrees with the decreased hepatic alanine content, Snat4 which is highly 
expressed in liver could explain this difference [46]. A previously unrecognized 
function of SNAT3 appears to be its role in histidine removal and metabolism by the 
liver. Liver is the main site of histidine metabolism, depending, at least in part, on 
uptake via SNAT3. 
Snat3 deficient mice also exhibited changes in the mTOR/S6K signaling 
pathway that plays a major role in sensing of intracellular amino acids and is involved 
in regulation of protein synthesis, energy metabolism, cellular proliferation, and body 
growth [35-36, 38]. mTOR activity is particularly sensitive to the availability of 
essential amino acids such as tryptophan, phenylalanine, arginine and leucine as 
well as also to glutamine [47] but also to glucose, insulin and insulin like growth factor 
1 (IGF1) levels [35]. Therefore, the decrease in glutamine, phenylalanine, tryptophan, 
glucose, insulin, and IGF1 availability observed in the Snat3-deficient mice could lead 
to the substantial reduction of the levels of the activated forms of both mTOR and 
S6K. Reduced activation of mTOR points to a collaboration between LAT1 and 
SNAT3 in providing amino acids for mTOR activation. Glutamine is taken by SNAT3 
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and can serve as an exchange substrate for leucine and tryptophan uptake by LAT1. 
Thus the role of SNAT3 in liver is similar to that of ASCT2 in cancer cells  and SNAT2 
in muscle cells [48-49]. Further, such a reduced mTOR signaling might be one 
reason why Snat3-deficient mice suffer from growth-retardation in the neonatal period 
[50]. 
SNAT3 properties and the cellular distribution within the liver suggest its 
involvement ammonia detoxification from the portal blood via the urea cycle [6, 21]. 
SNAT3 would deliver glutamine which is converted to glutamate which together with 
ammonium enters the urea cycle with urea finally excreted via kidneys. In the 
absence of Snat3, plasma ammonium levels remained unaltered whereas plasma 
urea levels were increased. We hypothesize that a reduced glutamine transport into 
periportal hepatocytes would result in a reduced NH4
+ production from the catabolism 
of glutamine to glutamate with reduced levels of NH4
+ available for ureagenesis. 
However, the increase in arginase (Arg1) and argininosuccinate lyase (Asl) observed 
in Snat3-deficient mice indicates that some compensatory mechanisms are in place 
to maintain urea production. Alternatively, low glucose levels may trigger increased 
protein catabolism to maintain energy production and the elevated urea levels and 
higher expression of enzymes may reflect enhanced formation of NH4
+ from protein 
break-down. A third possibility would be decreased renal clearance of urea [51], 
however, creatinine levels were in the normal range suggesting that renal function 
was not completely disturbed. Thus, the higher urea levels may be the result of 
disturbances at various levels and the early death of mutant animals complicates a 
detailed analysis.  
In brain, the deletion of Snat3 caused changes in the expression of several 
amino acid transporters as well of amino acid and neurotransmitter levels consistent 
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with a major role of the protein in the glutamate-glutamine cycle. Disrupted 
neurotransmitter synthesis could also explain the neurological disturbances seen in 
the Snat3-deficient mice. Glutamate released into the synapse is taken up by 
surrounding astrocytes via the Slc1a2 (Eaat2/Glt1) and Slc1a3 (Eaat1/Glast) 
glutamate transporters. Some glutamate is also taken up by Slc1a1 (Eaat3/Eaac1) 
transporters localized in neurons. After the conversion of glutamate to glutamine by 
glutamine synthetase, glutamine is released, possibly via Snat3 and/or Snat5 and 
taken up by neurons which may involve the Snat1 and Snat2 glutamine transporters 
for reconversion to glutamate by glutaminases [5, 15-17, 22, 42, 52-53]. The absence 
of Snat3 in the brain of mutant animals could therefore impair the release of 
glutamine from astrocytes and thereby affecting neuronal glutamate and GABA 
synthesis. The accumulation of glutamine correlated with the decrease of GABA and 
glutamate in the brain of mutant mice. The observed up-regulation of Snat1 and Lat1 
in mutant mice, which are thought to be involved in the uptake of glutamine into 
neurons and the release of glutamine from astrocytes, respectively, could be taken 
as an indicator of compensatory mechanisms. Concentrations of tyrosine and 
tryptophane, which are precursors of important neurotransmitters involved in 
cognitive functions, such as serotonin and dopamine, respectively, displayed reduced 
levels in mutant brain. Furthermore, the decrease of brain alanine concentrations 
might be explained by an increased Snat1-mediated alanine uptake as an additional 
source for glutamate synthesis [54].  Snat3 is also expressed in the endothelium of 
the blood brain barrier [19]. The elevated levels of glutamine in brain tissues may 
suggest that the main function of Snat3 at the blood-brain barrier is not the import of 
glutamine into the cerebro-spinal but the efflux of glutamine in coupling to other 
amino acid exchangers. Altogether, our results implicate Snat3 as critical if not as the 
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major facilitator of glutamine efflux from astrocytes in supply of glutamine for 
neurotransmitter synthesis. Cell-specific deletions of Snat3 and other members of the 
SLC38 family in brain are required to define their specific functions in 
neurotransmission. 
 In the kidney, glutamine is the primary metabolic source for the release of NH3, 
which when excreted as NH4
+ helps to save CO2 for de-novo synthesis of 
bicarbonate to restore systemic acid-base balance. Uptake of glutamine for 
ammoniagenesis has been attributed to Snat3 because Snat3 shows induction in 
parallel to increased ammoniagenesis [18, 20, 23]. Snat3-deficient mice showed a 
decrease in urinary ammonium excretion consistent with impaired ammoniagenesis. 
The up-regulation of the phosphate-dependent glutaminase (Pdg) as well as the 
down-regulation of Lat2 as a basolateral efflux pathway for glutamine, are likely a 
result of compensatory mechanisms to correct the decrease in glutamine availability. 
Similarly, the observed up-regulation in Pepck protein expression in kidney might 
indicate a compensation for a decrease of α-ketoglutarate availability. On the other 
hand, fasting increases Pepck-mRNA - apparently not reverted by glucose or insulin 
but by bicarbonate [55]. This suggests that increased Pepck in kidney are a measure 
of acidosis by impaired ammoniagenesis rather than of increased gluconeogenesis 
[55].  The early lethality in homozygous mutants made it impossible to conduct further 
metabolic experiments on renal functions. Since heterozygotic mice had reduced 
expression of SNAT3 we tested whether a partial defect in Snat3 could be 
functionally relevant during an oral acid load. Heterozygous mice showed similar 
changes in urinary pH and NH4
+ excretion as wildtype animals. However, 
heterozygous mice obviously required a higher induction of Pdg and Pepck mRNA 
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expression to achieve similar NH4
+ excretion rates suggesting that the partial loss of 
Snat3 impacts on ammoniagenesis.  
In conclusion, our results demonstrate that SNAT3 is a transporter for 
glutamine that is crucial for amino acid homeostasis in brain, liver and kidney. 
Moreover, signaling processes that mediate growth such as the mTOR/S6K pathway 
revealed changes that may also explain the retarded growth of animals lacking 
Slc38a3. Early lethality in mice prevented detailed analysis of organ-specific 
alterations and thus future studies on the physiological importance of SNAT3 and of 
glutamine need tissue-and cell-type specific deficiencies. 
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FIGURE LEGENDS 
 
FIGURE 1  
Snat3 point mutation leads to loss of Snat3 protein expression (A) Relative 
Snat3 mRNA expression in different organs of wildtype animals, n = 3. (B) Schematic 
model of the Snat3 transporter indicating the localization of the “C” to “T” mutation, 
“Slc38a3-Q263X”, causing a premature stop codon deleting the second half of the 
protein. The numbers below indicate the putative transmembrane domains. (C) At 
day 14 after birth, mutant animals were significantly smaller than wildtype (WT) 
animals (D,E,F) Relative mRNA expression of Snat3 was determined in brain, liver 
and kidney of wildtype, hetereozygous (Snat3+/-) and mutant (Snat3-/-) mice, n = 10-
12/genotype. (G,H,I) Protein expression of Snat3 was assessed in total membrane 
fractions from brain, liver and kidney. Snat3 protein was not detectable in the brain, 
liver and kidney of homozygous mutant animals (Snat3-/-)  and reduced in 
heterozygous (Snat3+/-) mice. All blots were tested for equal loading with -actin after 
stripping of membranes. (I) Presence of Snat3 (red) and Ace2 (green) staining in 
kidneys from wildtype animals and absence of Snat3 staining from homozygous 
mutant kidney. *P ≤ 0.05, ***P ≤ 0.001. 
 
FIGURE 2 
Plasma amino acid concentrations. Plasma amino acid concentrations were 
determined in 14 days old mice, all values are given in µmol/L, wildtype (WT) and 
homozygous mutant (Snat3-/-)  mice (n = 6).  *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
 
FIGURE 3 
Absence of Snat3 causes hypoglycemia and affects hepatic amino acid and 
glucose metabolism (A) Plasma glucose in ad libitum feeding mice was lower in 
homozygous mutant (Snat3-/-) mice, n = 8-27/genotype (B) Plasma insulin 
concentration in ad libitum feeding mice was reduced in homozygous mutant (Snat3-/-
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) animals, n = 9/genotype. (C,D,E) mRNA abundance of phosphoenolpyruvate 
carboxykinase (Pepck) was upregulated whereas glutamine synthetase (Glu1) and 
(Gls2) were downregulated at mRNA level in Snat3 deficient animals. (F-K) 
Expression of the phosphoenolpyruvate carboxykinase (Pepck) was increased 
whereas the abundance of glutaminase 2 (Gls2) and glutamine synthetase (Glu1) 
was downregulated. All blots were reprobed for -actin to control for loading and -
actin used for calculation of relative abundance. Normalized data are presented as 
bar graphs showing mean ± SEM. n = 11-12/genotype for qPCR, n = 5-6/genotype 
for immunoblots,  *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
 
FIGURE 4  
Snat3 mutant mice showed a disrupted hepatic mTOR/S6K pathway. (A, B, C) 
Quantification of hepatic amino acid concentrations for leucine (Leu), phenylalanine 
(Phe) and tryptophane (Trp), normalized against total protein (µmol.L-1/µg.µL-1), n = 
6/genotype. (D) Insulin-like growth factor 1 (Igf1) was significantly downregulated at 
mRNA level in homozygous mutant (Snat3-/-),  n = 11-12/genoytpe. (E-F) Bar graphs 
showing ratios of phosphorylated proteins to total proteins. (G-N) Immunoblotting for 
hepatic total non-phosphorylated and phosphorylated mammalian target of 
rapamycin (mTOR) and S6 Kinase (S6K). All blots were reprobed for -tubuline or -
actin to control for loading. Bar graphs show means ± SEM of the ratio of the protein 
of interest over loading control. Both total non-phosphorylated and phosphorylated 
mTOR were significantly downregulated in homozygous mutant Snat3 mice. Total 
S6K showed no difference in all mice, but phosphorylated S6K was massively 
reduced in Snat3 deficient mice. *P ≤ 0.05, **P ≤ 0.01 
 
FIGURE 5 
Snat3 deficiency affects urea cycle and metabolism. (A) Urea was significantly 
increased in the plasma of Snat3 deficient mice, n = 5-13/genotype. (B) Plasma 
ammonium levels were unchanged in all genotypes, n = 9-10/genotype. (C-F) mRNA 
expression of enzymes involved in the urea cycle. Carbamoyl phosphate synthetase I 
(Cps1) and ornithine transcarbamoylase (Otc) and were not altered, whereas 
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argininosuccinate lyase (Asl) and arginase 1 (Arg1) were upregulated in the liver from 
Snat3 deficient animals n = 11-12/genotype. *P ≤ 0.05.  
 
FIGURE 6  
Loss of Snat3 in the brain reduces neurotransmitter abundance and stimulates 
alternative transporter expression. (A, B, C) Quantification of amino acid 
concentrations in the brain. Brain of homozygous mutant Snat3 animals showed 
increased glutamine (Gln) levels but lower abundance of glutamate (Glu) and 
gamma-aminobutyric acid (GABA). Amino acid levels were normalized to total protein 
content (µmol.L-1/µg.µL-1), n = 6. (D-I) Brain mRNA expression of the sodium-coupled 
neutral amino acid transporter 1 (Snat1), 2 (Snat2), and 5 (Snat5), the excitatory 
amino-acid transporter 3 (Slc1a1), the excitatory amino-acid transporter 2 (Slc1a2), 
and glutamine synthetase (Glu1) were measured by RT-qPCR in all mice and only 
Snat5 mRNA was significantly reduced in Snat3 deficient mice, n = 10-12/genotype. 
(J-O) Immunoblotting for the sodium-coupled neutral amino acid transporter 1 
(Snat1), the excitatory amino-acid transporter 2 (Slc1a2), and the large neutral amino 
acid transporter 1 (Lat1). All membranes were reprobed for -actin to control for 
loading. Normalized protein expression was calculated and is shown in bar graphs. 
The glutamate transporter Slc1a2 showed no difference but Snat1 and Lat1 were 
upregulated in brains from Snat3 deficient mice. n=5/genotype, *P ≤ 0.05, **P ≤ 0.01.  
 
FIGURE 7   
Deletion of Snat3 affects renal ammoniagenesis and reduces urinary 
ammonium excretion. (A, B) Quantification of renal amino acid concentrations per 
total protein (µmol.L-1/µg.µL-1). Glutamine (Gln) and Glutamate (Glu) levels were both 
reduced in the kidneys of Snat3 deficient animals, n = 6/genotype. (C, D) 
Homozygous Snat3 mutant mice showed reduced urinary NH4
+ and urea excretion 
normalized to creatinine in the urine, n = 6-14/genotype. (E,F) Immunoblotting of 
phosphate dependent glutaminase (Pdg) and renal phosphoenolpyruvate 
carboxykinase (Pepck), n = 4/genotype. Pepck showed no difference but Pdg was 
upregulated in kidneys form Snat3 deficient mice. (J,K) Reduced expression of the 
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large neutral amino acid transporter 2 (Lat2) in the kidneys of Snat3 deficient mice. 
The membrane was reprobed for -actin to control for loading. Bar graph shows 
normalized protein expression.  
 
FIGURE 8 
Altered expression of key players of the ammoniagenic pathway in acid loaded 
Snat3 heterozygous mice. (A-E) Wildtype and Snat3 heterozygous mice were 
challenged with an oral acid load (NH4Cl) for 2 days. Both wildtype and heterozygous 
mice increased NH4
+ excretion per 24-hour urine, n = 4-6. Acid-challenged Snat3 
heterozygous mice showed a more pronounced increase in Pepck, Pdg but not 
Snat3 mRNA expression, n = 4-6/genotype. WT (displayed in white), WT after 2 days 
NH4Cl load (displayed in light grey), Snat3
-/- (displayed in black), after 2 days NH4Cl 
load (displayed in dark grey).   *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.  
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Suppl. Figure 1 mRNA expresssion of selected genes in kidneys from in Snat3-/-  
compared  to wild-type kidney samples (a-c) mRNA renal expression of the ammonia 
transporter Rhcg (Rhesus blood group family type C glycoprotein), the sodium-coupled neutral 
amino acid transporter 2 (Snat2) and 5 (Snat5) were measured by RT-qPCR in all mice, n = 10-
13/genotype. Rhcg and Snat2 showed no difference but Snat5 was downregulated in kidneys 
from Snat3 deficient mice. *P ≤ 0.05, **P ≤ 0.01 
Gene Acc. No. Primers Probes 
  
ARG2(M) 
  
AB047402 
  
F: 5’- GCT CCA AGC CAA AGT CCT TAG A-3’ 
(4-26) 
R: 5’-CCT CGA GGC TGT CCT TTT GA-3’ 
(46-66) 
  
5’-CCT CGA GGC TGT CCT TTT GA-3’ 
(28-48) 
ASL(M) NM_133768  F: 5’-CCCAAGGCACCTTCAAATTA-3’ 
(323-343) 
R: 5’-GCGACTTCGTCCTGTGTGTA-3’ 
(438-458) 
5’-GCCTGAAGGAACTCATCGGTGAAGC-3’ 
(383-408) 
ASS(M) MUSASSA01 F: 5’-GGCCAGGAAAGCAGACTACA-3’ 
(146-166) 
R: 5’-CACGAGGATGCAGGAGGT-3’ 
(268-286) 
5’-AAGGGCTCTGTGGTTCTGGCCTACA-3’ 
(212-23.7) 
CPS1(M) NM_001080809 F: 5’-TGTCCGAGATGCAGATGATAAC-3’ 
(1908-1930) 
R: 5’-ACATCTGGAACTCTGCATTGG-3’ 
(2038-2059) 
5’-CATGGGTGTTCACACAGGTGACTCG-3’ 
(1965-1990) 
GDH(M) NM_008133 F: 5’-ACCATGTGTTGAGCCTCTCC-3’ 
(338-358) 
R: 5’-GCCAGTGCTTTTACTTCATCC-3’ 
(474-495) 
5’-GGGAGGTATCCGTTACAGCA-3’ 
(441-461) 
GLU1(M) NM_008131  F: 5’-CAAGTGTGTGGAAGAGTTACCTGAGT-3’ 
(153-179) 
R: 5’-TGAAGGCTCCAACAGCGAC-3’ 
(209-228) 
5’-AACTTTGATGGCTCTAGTACCTTTCAG-3’ 
(180-207) 
HPRT(M) NM_013556 F: 5’-TTATCAGACTGAAGAGCTACTGTAAGATC-3’ 
(442-471) 
R: 5’-TTACCAGTGTCAATTATATCTTCAACAATC-3’ 
(539-568) 
5’-TGAGAGATCATCTCCACCAATAACTTTTATGTCCC-3’ 
(481-515) 
IGF1(M) NM_010512 F: 5’-AGATCTGCCTCTGTGACTTCTTG-3’ 
(38-61) 
R: 5’- CCTGTGGCCTTGTTGAAGTAA-3’ 
(213-238) 
5’-CACCTCTTCTACCTGGCGCTCTGCT-3’ 
(90-111) 
OTC(M) NM_008769 F: 5’-AAATTCGGGATGCACCTTC-3’ 
(628-647) 
R: 5’-GCTGCTTCCAGTGGATCATT-3’ 
(761-781) 
5’-GCAGAGCAGTATGCCAAGGAGAATGG-3’ 
(697-723) 
PEPCK(M) NM_028994 F: 5’-GTGGGCGATGACATTGCC-3’  
(1062-1079)  
R: 5’-ACTGAGGTGCCAGGAGCAAC-3’  
(1143-1162) 
5’-CCCAAGGCAACTTAAGGGCTATCAACCC-3’  
(1096-1123) 
PDG(M) XM_976581 F: 5’-ATGTGTTGGTCTCCTCTCTTGA-3’  
(1510-1532)  
R: 5’-TTGATCACCTCCTTCTCTCCG-3’  
(1642-1662) 
5’-AGATGGGCAACAGTGTTAAGGGAATTCACT-3’  
(1535-1564) 
RHCG(M) NM_019799  F: 5’-GTTGAAGAAGCGCAAGAA-3‘ 
(245-265) 
R: 5’-CGAAGACCATTGCGTGTACA-3’ 
(320-339) 
5’-TTACTATCGCTACCCGAGCTTCCAG-3’ 
(293-317) 
SLC1A1(M) NM_009199  F: 5’-TGTTTGACTGGCTCCTGGACC-3’ 
(472-493) 
R: 3’-GCTCCAGCTCCTTCTTCGAGA-3’ 
(1391-1412) 
5’-ATGCGTTTGGGACGGGCA-3’ 
(1361-1379) 
SLC1A2(M) NM_001077514 F: 5’-CCAGCAGATTGCAGACAGTGACAA-3’ 
(555-579) 
R: 5’-CCGCCTTGGTGGTATTGG-3’ 
(611-629) 
5’-TGGTGGCACCTCCATCCGAGG-3’ 
(587-608) 
SNAT1(M) NM_134086  F: 5’-CGCGTGCACACCAAAGTATG-3’  
(873-892) 
R: 5’-AGATTGGCAGGACGGACG-3’ 
(956-973) 
5’-TACCAACCATCGCCTTCGCGTTTG-3’ 
(923-946) 
SNAT2(M) NM_175121 F: 5’-CGTCCATCTCCTCCTCAAGA-3’ 
(732-752) 
R. 5’-CATTGGGGCTATGTCAAGCT-3’ 
(871-891)  
5’-GGCGTATGGTCTGGCTGGAAAGCTA-3’  
(798-823) 
SNAT3(M) NM_023805 F: 5'-CGAATCATGCCCACTGACAA-3‘ 
(1478-1497) 
R: 5'-AACCGCAGCGAAACAAAGG-3‘ 
(1531-1549) 
5'-AGCCTGCAAGATCCACCCCTAAAATCCT-3‘ 
(1500-1527) 
SNAT5(M) NM_172479 F: 5’-CCCTCACTGTGCCTGTTGTG-3’  
(1037-1057) 
R: 5’-CTTGCTTGGAAAGAGCAGCTG-3’  
(1083-1104) 
5’-CCCTATCCGCCGAGCCCTCCA-3’  
(1062-1083) 
Supl. Table 1 Primers and probes 
Amino acid  Wildtype  
(µmol/L)  
Snat3-/- 
(µmol/L)  
Alanine (Ala) 778.82 ± 45.07 541.17 ± 26.83*** 
Arginine  (Arg) 196.45 ± 25.35 153.73 ± 12.64 
Argininosuccinic acid (Asa) n.d. n.d. 
Anserine (Ans) n.d. n.d. 
Asparagine (Asn) 108.26 ± 6.65 120.13 ± 5.39 
Aspartic acid (Asp) 28.59 ± 4.82 20.83 ± 2.51 
α-Aminoadipic acid (Aad) n.d. n.d. 
α-amino-n-butyric acid (Abu) 16.50 ± 3.12 20.27 ± 2.98 
β-Aminoisobutyric (bAib) n.d. n.d. 
Carnosine (Car) 9.88 ± 0.78 20.50 ± 3.03*** 
Citruline (Cit) 102.97 ± 4.15 103.67 ± 3.54 
Cystathionine (Cth) n.d. n.d. 
Cysteine (Cys) 3.05 ± 0.04 3.31 ± 0.20** 
Ethanolamine (EtN) 31.11 ± 2.35 40.83 ± 8.05 
GABA n.d. n.d. 
Glutamate (Glu) 87.91 ± 10.75 63.83 ± 7.57 
Glutamine (Gln) 827.91 ± 43.67 831.25 ± 46.41 
Glycine (Gly) 623.55 ± 32.83 676.08 ± 67.07 
Histidine (His) 120.99 ± 12.09 469.36 ± 39.54*** 
Hydroxylysine (Hyl) n.d. n.d. 
Hydroxyproline (Hyp) 88.75 ± 5.68 80.28 ± 9.51 
Isoleucine (Ile) 95.07 ± 4.35 120.35 ± 14.40 
Leucine (Leu) 133.36 ± 7.79 191.95 ± 26.84* 
Lysine (Lys) 472.00 ± 34.97 424.50 ± 31.25 
Methionine (Met) 92.20 ± 9.53 75.37 ± 5.40 
o-Phosphoethanolamine (PEtN) 18.81 ± 0.09 13.88 ± 2.27 
Ornithine (Orn) 152.09 ± 14.37 134.57 ± 12.20 
Phenylalanine (Phe) 80.28 ± 4.05 86.02 ± 5.38 
Proline (Pro) 309.09 ± 25.60 241.25 ± 19.09 
Serine (Ser) 308.64 ± 20.50 39.25 ± 22.10 
Taurine (Tau) 689.00 ± 77.36 608.67 ± 66.96 
Threonine (Thr) 231.45 ± 26.81 293.92 ± 14.45* 
Tryptophane (Trp) 87.70 ± 4.43 67.30 ± 6.01** 
Tyrosine (Tyr) 150.32 ± 13.41 95.08 ± 9.47** 
Valine (Val) 216.27 ± 10.31 266.25 ± 33.31 
Supl. Table 2 Plasma amino acid concentration in Snat3-/- compared to wildtype mice 
*P-value < 0.05, **P-value < 0.01, ***P-value < 0.001 
Supl. Table 3 Liver amino acid content in Snat3-/- compared to wild-type mice 
 Amino acid  Wildtype 
(µmol.L-1/µg protein.µL-1)  
Snat3-/- 
(µmol.L-1/µg protein.µL-1)  
Alanine (Ala) 57.52 ± 9.72 28.99 ± 4.99 ** 
Arginine  (Arg) 0.15 ± 0.01 0.14 ± 0.03 
Argininosuccinic acid (Asa) n.d. n.d. 
Anserine (Ans) 0.06 ± 0.04 0.02 ± 00 ** 
Asparagine (Asn) 3.67 ± 0.32 1.82 ± 0.24 ** 
Aspartic acid (Asp) 11.46 ± 3.49 10.46 ± 3.53 
α-Aminoadipic acid (Aad) 1.18 ± 0.31 1.62 ± 0.24 
α-Amino-n-butyric acid (Abu) 1.59 ± 0.15 2.28 ± 0.46 
β-Aminoisobutyric (bAib) 1.81 ± 0.05 4.25 ± 0.68 
Carnosine (Car) 0.24 ± 0.09 0.19 ± 0.03 
Citruline (Cit) 1.17 ± 0.11 20.9 ± 0.36 * 
Cystathionine (Cth) 0.43 ± 0.12 0.34 ± 0.06 
Cysteine (Cys) 0.08 ± 0.02 0.06 ± 0.02 
Ethanolamine (EtN) 2.05 ± 0.37 2.30 ± 0.88 
GABA 0.58 ± 0.05 0.62 ± 0.09 
Glutamate (Glu) 67.40 ± 6.96 42.88 ± 11.46 ** 
Glutamine (Gln) 84.02 ± 10.11 36.76 ± 7.63** 
Glycine (Gly) 47.75 ± 5.74 45.20 ± 4.59 
Histidine (His) 9.25 ± 0.74 8.32 ± 0.91 
Hydroxylysine (Hyl) n.d. n.d. 
Hydroxyproline (Hyp) 1.75 ± 0.15 15.68 ± 1.77 * 
Isoleucine (Ile) 3.65 ± 0.31 2.17 ± 0.29 ** 
Leucine (Leu) 6.22 ± 0.57 4.26 ± 0.47 
Lysine (Lys) 7.90 ± 0.88 7.75 ± 0.88 
Methionine (Met) 0.53 ± 0.05 0.28 ± 0.06 
o-Phosphoethanolamine (PEtN) 21.65 ± 1.60 16.95 ± 3.01 
Ornithine (Orn) 8.07 ± 0.97 5.36 ± 1.07 
Phenylalanine (Phe) 2.37 ± 0.28 1.20 ± 0.21 * 
Proline (Pro) 9.09 ± 0.99 6.08 ± 0.94 
Serine (Ser) 11.80 ± 1.16 15.68 ± 1.77 
Taurine (Tau) 333.04 ± 40.88 172.74 ± 38.11 * 
Threonine (Thr) 7.91 ± 0.48 9.60 ± 0.84 ** 
Tryptophane (Trp) 1.00 ± 0.09 0.50 ± 0.06 
Tyrosine (Tyr) 2.88 ± 0.30 1.48 ± 0.18 ** 
Valine (Val) 5.96 ± 0.51 3.81 ± 0.49 * 
*P-value < 0.05, **P-value < 0.01, ***P-value < 0.001 
Amino acid  Wildtype 
(µmol.L-1/µg protein.µL-1)  
Snat3-/- 
(µmol.L-1/µg protein.µL-1)  
Alanine (Ala) 65.55 ± 4.18  40.02 ± 3.40 ** 
Arginine  (Arg) 10.53 ± 0.62 9.23 ± 0.62 
Argininosuccinic acid (Asa) 0.45 ± 0.09 0.43 ± 0.06 
Anserine (Ans) 0.24 ± 0.03 0.35 ± 0.01 ** 
Asparagine (Asn) 8.07 ± 0.46  3.80 ± 0.31 ** 
Aspartic acid (Asp) 87.35 ± 10.04 34.02 ± 7.71 ** 
α-Aminoadipic acid (Aad) 0.74 ± 0.09 0.67 ± 0.07  
α-Amino-n-butyric acid (Abu) 1.88 ± 0.13  1.31 ± 0.24  
β-Aminoisobutyric (bAib) 1.02 ± 0.27  0.98 ± 0.19  
Carnosine (Car) 3.0 ± 0.46 0.35 ± 0.01 ** 
Citruline (Cit) 2.33 ± 0.16 2.63 ± 0.16  
Cystathionine (Cth) 4.36 ± 0.95 3.17 ± 0.47 
Cysteine (Cys) n.d. n.d. 
Ethanolamine (EtN) 13.61 ± 2.44 19.26 ± 4.20 
GABA 206.45 ± 20.80  154.73 ± 16.49  ** 
Glutamate (Glu) 325.78 ± 22.12  167.15 ± 9.46  **  
Glutamine (Gln) 225.13 ± 12.40  371.73 ± 19.36  **  
Glycine (Gly) 107.44 ± 11.72 151.84 ± 1402 
Histidine (His) 5.72 ± 0.52  14.26 ± 2.80 ** 
Hydroxylysine (Hyl) n.d. n.d. 
Hydroxyproline (Hyp) 4.14 ± 0.47  3.57 ± 1.15 
Isoleucine (Ile) 3.42 ± 0.33  2.20 ± 0.33 * 
Leucine (Leu) 4.84 ± 0.59  3.58 ± 0.62 * 
Lysine (Lys) 21.38 ± 1.34 36.37 ± 3.33 ** 
Methionine (Met) 4.28 ± 0.81  1.40 ± 0.19 ** 
o-Phosphoethanolamine (PEtN) 160.36 ± 6.44  216.52 ± 24.08 
Ornithine (Orn) 1.27 ± 0.13  1.24 ± 0.09  
Phenylalanine (Phe) 3.90 ± 0.36  2.39 ± 0.29 ** 
Proline (Pro) 9.15 ± 0.62 10.82 ± 1.14 
Serine (Ser) 72.86 ± 2.80 57.80 ± 4.76 * 
Taurine (Tau) 1205.68  ± 39.27 1527.71 ± 104.80 ** 
Threonine (Thr) 27.49 ± 3.16  18.86 ± 2.12  
Tryptophane (Trp) 2.23 ± 0.14 1.06 ± 0.12 ** 
Tyrosine (Tyr) 7.08 ± 0.94  2.24 ± 0.23 **  
Valine (Val) 6.90 ± 0.63  3.76 ± 0.58 ** 
Supl. Table 4 Brain amino acid content in Snat3-/- compared to wild-type mice 
 
*P-value < 0.05, **P-value < 0.01, ***P-value < 0.001 
Amino acid  Wildtype 
(µmol.L-1/µg protein.µL-1)  
Snat3-/- 
(µmol.L-1/µg protein.µL-1)  
Alanine (Ala) 43.13 ± 4.13 28.32 ± 3.34 
Arginine  (Arg) 5.60 ± 0.20 4.15 ± 0.25 ** 
Argininosuccinic acid (Asa) 0.46 ± 0.04 0.28 ± 0.03 ** 
Anserine (Ans) 0.05 ± 0.01 0.04 ± 00 
Asparagine (Asn) 7.51 ± 0.74 6.17 ± 0.60 
Aspartic acid (Asp) 41.95 ± 2.62 28.33 ± 1.81 ** 
α-Aminoadipic acid (Aad) 1.55 ± 0.07 1.26 ± 0.17 
α-amino-n-butyric acid (Abu) 1.45 ± 0.13 3.10 ± 0.92 * 
β-Aminoisobutyric (bAib) 1.11 ± 0.05 1.84 ± 0.29 ** 
Carnosine (Car) 0.45 ± 0.04 0.4 ± 0.07 
Citruline (Cit) 1.64 ± .014 1.68 ± 0.16 
Cystathionine (Cth) 0.25 ± 0.03 0.17 ± 0.01 * 
Cysteine (Cys) 80.6 ± 0.25 8.30 ± 0.80 
Ethanolamine (EtN) 11.81 ± 0.75 17.44 ± 2.50 
GABA 1.42 ± 0.13 1.31 ± 0.09 
Glutamate (Glu) 146.70 ± 3.43 120.34 ± 6.86 ** 
Glutamine (Gln) 30.76 ± 2.68 23.29 ± 2.89 * 
Glycine (Gly) 152.27 ± 7.52 171.19 ± 18.20 
Histidine (His) 3.79 ± 0.38 12.28 ± 2.39 ** 
Hydroxylysine (Hyl) 0.26 ± 0.02 0.15 ± 0.02 ** 
Hydroxyproline (Hyp) 14.72 ± 1.30 6.95 ± 2.08 * 
Isoleucine (Ile) 4.56 ± 0.25 4.00 ± 0.12 
Leucine (Leu) 7.82 ± 0.51 7.56 ± 0.32 
Lysine (Lys) 9.12 ± 0.37 8.42 ± 0.93 
Methionine (Met) 1.71 ± 0.11 1.07 ± 0.19 ** 
o-Phosphoethanolamine (PEtN) 79.98 ± 2.81 90.12 ± 5.15 
Ornithine (Orn) 2.12 ± 0.09 1.57 ± 0.13 ** 
Phenylalanine (Phe) 3.24 ± 0.15 3.12 ± 0.20 
Proline (Pro) 18.35 ± 1.95 12.36 ± 1.26 
Serine (Ser) 25.93 ± 2.04 22.48 ± 2.89 
Taurine (Tau) 337.52 ± 11.63 348.49 ± 35.33 
Threonine (Thr) 15.05 ± 1.12 16.08 ± 2.23 
Tryptophane (Trp) 1.64 ± 0.02 1.18 ± 0.09 ** 
Tyrosine (Tyr) 5.34 ± 0.61 2.92 ± 0.24 ** 
Valine (Val) 9.00 ± 0.45 7.81 ± 0.31 
Supl. Table 5 Kidney amino acid content in Snat3-/- compared to wild-type mice 
 
*P-value < 0.05, **P-value < 0.01, ***P-value < 0.001 
